Filing Flows › 4D Molecular Therapeutics (FDMT) › Q2 2026 › vs Q1 2026
4D Molecular Therapeutics (FDMT) Q2 2026 vs Q1 2026 (quarter over quarter)
4D Molecular Therapeutics's revenue rose $734K (+24%) from $3.0M in Q1 2026 to $3.8M in Q2 2026.
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $3.8M | $3.0M | $734K | +24% |
| Other income, net | $4.1M | $4.9M | −$771K | -16% |
| Net loss | $72.9M | $68.8M | $4.2M | +6% |
| Costs & expenses | $80.8M | $76.7M | $4.1M | +5% |
| Operating costs | $80.8M | $76.7M | $4.1M | +5% |
| Research & development | $68.3M | $65.0M | $3.3M | +5% |
| General & admin | $12.5M | $11.7M | $837K | +7% |
| Operating cash sources | $77.2M | $73.8M | $3.3M | +4% |
| Depreciation & amortization | $1.3M | $1.3M | $11K | +0.9% |
| Share-based compensation | $5.9M | $4.5M | $1.4M | +32% |
| Cash used in operations | $70.0M | $68.1M | $1.9M | +3% |
| Net loss absorbed | $72.9M | $68.8M | $4.2M | +6% |
| Working capital & other | $4.2M | $5.1M | −$860K | -17% |
Questions
How much did 4D Molecular Therapeutics's revenue grow quarter over quarter in Q2 2026?
4D Molecular Therapeutics's revenue rose $734K (+24%) from $3.0M in Q1 2026 to $3.8M in Q2 2026.